653592-04-2

Basic information

• Product Name: MT-DADMe-ImmA
• Synonyms: MTDIA;MT-DADMe-ImmA HCl;Methylthio-DADMe-Immucillin A;METHYLTHIO-DADME-IMMUCILLIN A; MTDIA;MTDIA; MTDIA HCL; METHYLTHIO-DADME-IMMUCILLIN A; MT-DADME-IMMA; MT-DADME-IMMA HCL;(3R,4S)-1-((4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((methylthio)methyl)pyrrolidin-3-ol;3-Pyrrolidinol, 1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylthio)methyl]-, (3R,4S)-
• CAS NO: 653592-04-2
• Molecular Formula: C13H19N5OS
• Molecular Weight: 293.38786
• EINECS: -0
• Mol File: 653592-04-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 108-110 °C
• Boiling Point: 566.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.412±0.06 g/cm3(Predicted)
• PKA: 14.13±0.40(Predicted)
• CAS DataBase Reference: MT-DADMe-ImmA(CAS DataBase Reference)
• NIST Chemistry Reference: MT-DADMe-ImmA(653592-04-2)
• EPA Substance Registry System: MT-DADMe-ImmA(653592-04-2)

Safety Data

• Hazardous Substances Data: 653592-04-2(Hazardous Substances Data)

Usage

Description

MT-DADMe-ImmA is an inhibitor of 5'-methylthioadenosine phosphorylase (MTAP) with a Ki value of 1.7 nM. It is known to increase the levels of MTA, a product of polyamine metabolism, in FaDu human squamous cell carcinoma cells when used at a concentration of 1 μM. Additionally, MT-DADMe-ImmA has demonstrated the ability to reduce tumor growth in a FaDu mouse xenograft model when administered at dosages of 5, 9, and 21 mg/kg per day for 28 days.

Uses

Used in Cancer Treatment:
MT-DADMe-ImmA is used as an anticancer agent for the treatment of various types of cancer. Its application is based on its ability to inhibit the enzyme MTAP, which in turn increases the levels of MTA in cancer cells, leading to reduced tumor growth. This makes MT-DADMe-ImmA a promising candidate for cancer therapy.
Used in Drug Development:
MT-DADMe-ImmA is used as a lead compound in the development of new drugs targeting MTAP. Its high potency and selectivity for MTAP make it an attractive starting point for designing more effective and targeted cancer treatments.
Used in Preclinical Research:
MT-DADMe-ImmA is used as a research tool in preclinical studies to investigate the role of MTAP in cancer and to evaluate the potential of MTAP inhibition as a therapeutic strategy. Its use in FaDu mouse xenograft models allows researchers to study the effects of MTAP inhibition on tumor growth and to assess the potential of MT-DADMe-ImmA as a therapeutic agent in vivo.
Used in Pharmaceutical Industry:
MT-DADMe-ImmA is used as a key compound in the pharmaceutical industry for the development of novel cancer treatments. Its ability to inhibit MTAP and reduce tumor growth makes it a valuable asset in the search for new and effective cancer therapies.

Upstream product

• 2320-75-4 ethyl 4-amino-5H-pyrrolo[3,2-d]pyrimidine-7-carboxylate 
• 50-00-0 formaldehyd 
• 2227-98-7 9-Deazaadenine 
• 267421-93-2 (3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidine 
• 253129-03-2 (3R, 4R)-1-benzyl-4-(hydroxymethyl)pyrrolidin-3-ol 
• 635319-09-4 tert-butyl (3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 666831-17-0 (3R,4S)-1-[(7-benzyloxymethyl-6-tert-butoxy-9-deazapurin-9-yl)methyl]-3-hydroxy-4-methylthiomethylpyrrolidine hydrochloride 
• 666831-18-1 (3R,4S)-1-acetoxy-[(7-benzyloxymethyl-6-tert-butoxy-9-deazahypoxanthin-9-yl)methyl]-4-methylthiomethylpyrrolidine 
• 666831-26-1 (3R,4S)-tert-butyl 3-hydroxy-4-((methylthio)methyl)pyrrolidine-1-carboxylate 
• 666831-19-2 (3R,4S)-1-[(7-benzyloxymethyl-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-methylthiomethylpyrrolidine 
• 84905-80-6 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine 
• 5655-01-6 9-deazahypoxanthine 
• 252932-48-2 3-amino-2-ethoxycarbonylpyrrole 
• 871086-00-9 (3S,4R)-1-benzyl-4-hydroxy-5-oxopyrrolidine-3-carboxylic acid 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THERAPY OF PROSTATE CANCER USING DRUG COMBINATIONS TO TARGET POLYAMINE BIOSYNTHESIS AND RELATED PATHWAYS

Provided are compositions and methods for treating prostate conditions. The methods involve administering to an individual in need thereof a composition that contains i) an inhibitor of methionine salvage pathway in prostate of the individual and ii) a polyamine analogue. The methods are for use in individuals who have been diagnosed with, or are suspected of having or at risk for developing androgen sensitive prostate cancer (AS-CaP), or Castration recurrent CaP (CR-CaP), or benign prostate hyperplasia (BPH). The disclosure includes use of inhibitors of methylthioadenosine phosphorylase (MTAP), and a polyamine analog that upregulates polyamine catabolism by increasing spermidine/spermine Nl -acetyl transferase (SAT1) activity, such as methylthio-DADMe-Immucillin (MTDIA), andl),N(11)-bisethylnorspermine (BENSpm), respectively. Pharmaceutical formulations that contain a combination of the inhibitor of the methionine salvage pathway and a polyamine analogue are included, as are kits that contain such agents.

SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA)

The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methylthiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5'-methylthioadenosine phosphorylase (MTAP).

INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES

The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds